{
    "clinical_study": {
        "@rank": "129524", 
        "acronym": "DECIDE", 
        "arm_group": {
            "arm_group_label": "Practicing urologic surgeons", 
            "description": "Performing at least 60 radical prostate surgeries annually"
        }, 
        "brief_summary": {
            "textblock": "This clinical utility study pilot is based on a review of real but de-identified and\n      randomized patient cases and aims to evaluate Urologists' treatment recommendations before\n      and after reviewing the results provided by the Decipher test.   This is a pilot study and\n      the primary intent is to help guide development and design of future clinical utility\n      studies for Decipher"
        }, 
        "brief_title": "Decision Impact Study to Measure the Influence of DECIPHER on Treatment Recommendations", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The primary and secondary objectives will be assessed in retrospectively selected prostate\n      cancer patients treated with radical prostatectomy with one or more adverse pathological\n      features (APFs)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Criteria (Participant enrollment)\n\n        Inclusion Criteria Study participants:\n\n          1. Practicing board-certified urologic surgeons\n\n          2. Performing at least 40 radical prostate surgeries annually\n\n        Exclusion Criteria Study Participants:\n\n        (1) Did not meet the inclusion criteria\n\n        Criteria (Case selection)\n\n        Inclusion Criteria Case File:\n\n        Patient cases eligible for this study were treated with radical prostatectomy and have one\n        or more adverse pathological features present defined as:\n\n        Pathological Gleason score >= 8 or Gleason score 7 with primary pattern 4; Pathological\n        stage T3A (= Extraprostatic extension) or T3B (=Seminal vesicle invasion); Positive\n        surgical margins Gleason grade upgrade from biopsy to surgery\n\n        Exclusion Criteria Case File:\n\n        Metastatic disease (M+) prior to surgery Received any neo-adjuvant prostate cancer\n        treatment with radical prostatectomy (radiation, hormone, chemotherapy)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "This is an exploratory study utilizing archived tumor specimens and demographic and\n        pathologic characteristics derived from the patient's medical charts.  The study\n        participants are the urologists who review the selected case files."
            }
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02020876", 
            "org_study_id": "CU001"
        }, 
        "intervention": {
            "arm_group_label": "Practicing urologic surgeons", 
            "description": "Participants are asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation.  All participants use the same data collection instrument. Each participant opinion is collected based on a random selection of cases.", 
            "intervention_name": "DECIPHER Questionnaire", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 19, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Diego", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92121"
                }, 
                "name": "GenomeDx Bioscience Inc."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "GenomeDx Decipher Test for Metastatic Disease in Prostate Cancer for Patients With Adverse Pathology Post Radical Prostatectomy: Does it Impact Physician Decision Making?", 
        "overall_official": [
            {
                "affiliation": "GenomeDx Biosciences Inc.", 
                "last_name": "Elai Davicioni, pHd", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Department of Urology, Columbia University, New York, NY USA", 
                "last_name": "Badani Ketan, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To determine the extent to which the use of the Decipher test influences treatment recommendations by physicians post radical prostatectomy (RP).\nThis decision impact study aims to evaluate Urologists' treatment recommendations before and after reviewing the results provided by the Decipher test.", 
            "measure": "Change in treatment recommendation", 
            "safety_issue": "No", 
            "time_frame": "1.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02020876"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "23592338", 
            "citation": "Badani K, Thompson DJ, Buerki C, Davicioni E, Garrison J, Ghadessi M, Mitra AP, Wood PJ, Hornberger J. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget. 2013 Apr;4(4):600-9."
        }, 
        "secondary_outcome": {
            "description": "Changes in Urologists expressed level of confidence in the treatment recommendation as measured by the response to item 4a in the eCRF survey.\nUrologist's perception regarding the utility of the Decipher test as measured by the responses to question 4b and 38b and 38c in the eCRF survey.\nAgreement in treatment recommendation", 
            "measure": "Urologist's perception regarding the utility of the Decipher", 
            "safety_issue": "No", 
            "time_frame": "1.5 years"
        }, 
        "source": "GenomeDx Biosciences Corp", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GenomeDx Biosciences Corp", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}